Member Info for Brand

Re: why didn't they mention sng001/synairgen, but talk glowingly about inhaled inf and 'the company' - you can't market an unapproved drug in the USA. Simple as.

Thank you for sharing Wigster, lots of good stuff in there.

Link to the live stream - KO @ 2pm EST

https://coronavirus.house.gov/subcommittee-activity/hearings/preparing-and-preventing-next-public-health-emergency-lessons-learned

From Activ TLR rns

"About ACTIV-2

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) was a public-private partnership to develop a coordinated research strategy to accelerate the development of the most promising COVID-19 treatments and vaccines (Protocol ACTIV-2/A5401; "Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt out COVID)"). ACTIV-2 is an adaptive Phase 2/3 trial testing agents in non-hospitalised adults experiencing mild to moderate COVID-19 sponsored by NIAID, part of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).

[1] One participant randomized to placebo did not receive study intervention and was excluded from all analyses. The treated population therefore included 220 participants (110 SNG001, 110 placebo).

[2] Synairgen conducted a trial of SNG001 in high-risk, home-based COVID-19 patients (SG016) in which fewer patients treated with SNG001 were hospitalised (0/56) compared to placebo (2/58). In total across SG016 and ACTIV-2, 1/165 SNG001-treated home-based COVID-19 patients have been hospitalised."

6 sites in Canada can capture 70%+ of the population

Sng001 is highly effective in early treatment - see Activ, sg016

The obvious Univ Southampton link

The panel w p Monk, rick bright repeatedly mentioned early use of inhaled inf and large scale platform trials - RB named checked recovery more than once.

Approval in Canada would open the door pretty much everywhere in the world.

So there is certainly a chance it fits.

I've recently come around to the idea that the strive launch is tied to the 'Project Covid Shield' $8.5B funding bill.

The new layout looks good. A lot more information included and some of the posters here could probably have a look at the FAQ before the next time they post

Andy - 'kinell mate still at it? Lol

Remind me what platform trials have been announced w/o sng001

https://www.medrxiv.org/content/10.1101/2022.11.25.22282759v1.article-info

https://www.google.com/amp/s/thehill.com/policy/healthcare/3756877-fda-pauses-authorization-for-last-remaining-covid-19-monoclonal-antibody-treatment/amp/

Initially replied on the wrong thread soz

Daneeka - it was 'registered offices' I was referring to, point taken.

Also re EU - again point taken but what we have here is a very recent document (28 Nov) spelling out the urgent need and willingness to support "broad spectrum anti-virals" and for HERA to work together with BARDA

Cheers Prion,

I don't know the specifics of it, but I do know SNG have offices in Ireland, Spain and if I remember correctly Brussels. Happy to be corrected on locations and can't speak to the exact eligibility for EU funding etc.

Looking through the docs in detail, there seems to be reference to the ESWI conference which I below T Wilkinson spoke at on behalf of the company

https://health.ec.europa.eu/document/download/ff17bd26-4cdd-4351-a4e3-e2ca85aa3e84_en?filename=wp2023_annex_en.pdf

Page 85

Published 28 Nov. Seems very good.

"Broad-spectrum anti-viral therapeutics are increasingly recognised as one of the tools to be pursued more actively in the context of pandemic preparedness. While vaccines are important to prevent infection or severe disease, therapeutics are equally important to save the lives of infected persons and might possibly prevent infection"

https://research-and-innovation.ec.europa.eu/news/all-research-and-innovation-news/european-commission-progresses-cooperation-development-and-availability-key-therapeutics-pandemic-2022-11-28_en

Lots more info avail in the links within the doc.

A new job ad:

https://www.synairgen.com/careers/lab-technician

Anyone remember the sprinter results for loss of smell and taste?

https://www.forbes.com/sites/williamhaseltine/2022/08/09/loss-of-smell-linked-to-long-term-covid-cognitive-impairment/?sh=a394a4540d76

Sure. They gutted their airlines chasing the LCC profit bonanza, made a few quid while the legacy brands still had appeal and now have a low cost service with a legacy cost base and a terrible consumer reputation ;-)

LOL

"Antibiotics like the penicillins have saved millions of lives, in part because they can stop a bacterial infection before anyone understands the microbe causing it. But no such broad-spectrum medicine exists to stop viral infections, leaving the world open to emerging viral threats like COVID-19.

This panel discussion, sponsored by Synairgen and live-streamed from the National Press Club in Washington D.C., will highlight new discoveries that could lead to the world's first broad-spectrum antivirals, including inhaled medicines that would make emerging infections easier to treat. Together, these medicines could have the potential to stymie pathogens as diverse as influenza, adenovirus, RSV — and COVID-19."

The conference is Wednesday in San Diego. This is Tuesday in DC